A New Oleanolic Acid Derivative Against CCl₄-Induced Hepatic Fibrosis in Rats
Overview
Chemistry
Molecular Biology
Authors
Affiliations
A novel hepatoprotective oleanolic acid derivative, 3-oxours-oleana-9(11), 12-dien-28-oic acid (Oxy-Di-OA), has been reported. In previous studies, we found that Oxy-Di-OA presented the anti-HBV (Hepatitis B Virus) activity (IC = 3.13 µg/mL). Remarkably, it is superior to lamivudine in the inhibition of the rebound of the viral replication rate. Furthermore, Oxy-Di-OA showed good performance of anti-HBV activity in vivo. Some studies showed that liver fibrosis may affiliate with HBV gene mutations. In addition, the anti-hepatic fibrosis activity of Oxy-Di-OA has not been studied. Therefore, we evaluated the protective effect of Oxy-Di-OA against carbon tetrachloride (CCl₄)-induced liver injury in rats. Daily intraperitoneally administration of Oxy-Di-OA prevented the development of CCl₄-induced liver fibrosis, which was evidenced by histological study and immunohistochemical analysis. The entire experimental protocol lasted nine weeks. Oxy-Di-OA significantly suppressed the increases of plasma aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ( < 0.05). Furthermore, Oxy-Di-OA could prevent expression of transforming growth factor β1 (TGF-β1). It is worth noting that the high-dose group Oxy-Di-OA is superior to bifendate in elevating hepatic function. Compared to the model group, Oxy-Di-OA in the high-dose group and low-dose group can significantly reduce the liver and spleen indices ( < 0.05). The acute toxicity test showed that LD and a 95% confidence interval (CIs) value of Oxy-Di-OA were 714.83 mg/kg and 639.73-798.73 mg/kg via intraperitoneal injection in mice, respectively. The LD value of Oxy-Di-OA exceeded 2000 mg/kg via gavage in mice. In addition, a simple and rapid high performance liquid chromatography-ultraviolet (HPLC-UV) method was developed and validated to study the pharmacokinetic characteristics of the compound. After single-dose oral administration, time to reach peak concentration of Oxy-Di-OA (C = 8.18 ± 0.66 μg/mL) was 10 ± 2.19 h; the elimination half-life and area under the concentration-time curve from = 0 to the last time of Oxy-Di-OA was 2.19 h and 90.21 μg·h/mL, respectively.
DMello R, Mendon V, Pai P, Das I, Sundara B 3 Biotech. 2025; 15(3):56.
PMID: 39926108 PMC: 11803024. DOI: 10.1007/s13205-025-04209-5.
Lachica M, Borras-Linares I, Borges T, Nieto R, Seiquer I, Garcia-Contreras C Animals (Basel). 2024; 14(19).
PMID: 39409775 PMC: 11475709. DOI: 10.3390/ani14192826.
Principal Bioactive Properties of Oleanolic Acid, Its Derivatives, and Analogues.
Jannus F, Sainz J, Reyes-Zurita F Molecules. 2024; 29(14).
PMID: 39064870 PMC: 11279785. DOI: 10.3390/molecules29143291.
Oleanolic acid and its analogues: promising therapeutics for kidney disease.
Pan D, Qu Y, Shi C, Xu C, Zhang J, Du H Chin Med. 2024; 19(1):74.
PMID: 38816880 PMC: 11140902. DOI: 10.1186/s13020-024-00934-w.
Deng J, Qin L, Zhou Z Drug Des Devel Ther. 2023; 17:2335-2351.
PMID: 37576085 PMC: 10416792. DOI: 10.2147/DDDT.S412818.